Review: Optimizing outcomes with alosetron hydrochloride in severe diarrhea-predominant irritable bowel syndrome
Irritable bowel syndrome (IBS) is a highly prevalent functional gastrointestinal disorder that causes a range of symptoms. Currently, alosetron hydrochloride (Lotronex ® ), a selective serotonin type 3 receptor antagonist, is the only medication approved for the treatment of severe diarrhea-predomin...
Main Author: | Susan L. Lucak MD |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2010-05-01
|
Series: | Therapeutic Advances in Gastroenterology |
Online Access: | https://doi.org/10.1177/1756283X10362277 |
Similar Items
-
Targeted therapies for diarrhea-predominant irritable bowel syndrome
by: Olden KW
Published: (2012-05-01) -
Diagnosis and treatment of diarrhea-predominant irritable bowel syndrome
by: Lacy BE
Published: (2016-02-01) -
Eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome
by: Özdener AE, et al.
Published: (2017-09-01) -
Characterization of kynurenine pathway in patients with diarrhea-predominant irritable bowel syndrome
by: Pingping Li, et al.
Published: (2020-06-01) -
TREATMENT OF DIARRHEA-PREDOMINANT IRRITABLE BOWEL SYNDROME WITH MESALAZINE AND/OR SACCHAROMYCES BOULARDII
by: Mauro BAFUTTO, et al.
Published: (2013-12-01)